Benefits
FDA-authorized cholesterol claim: the strongest evidence on this page
FDA 1997 health claim (21 CFR 101.81): 3 g/day of beta-glucan soluble fiber from oats or barley, as part of a diet low in saturated fat and cholesterol, may reduce the risk of coronary heart disease. Foods carrying it must supply at least 0.75 g of soluble fiber per serving. FDA authorized it on 23 January 1997 in response to a petition from The Quaker Oats Company; it was not FDA's first health claim, since claims such as calcium and osteoporosis were authorized in 1993. EFSA authorized a parallel EU claim in 2010. Two independent meta-analyses agree on the size of the effect: 28 trials found LDL 0.25 mmol/L and total cholesterol 0.30 mmol/L below control, and 58 trials in 3,974 people at a median 3.5 g/day found LDL 0.19 mmol/L below control, roughly a 5 to 7 percent fall from a typical starting LDL. Most extensively-studied dietary fiber for cardiovascular risk. Effect size comparable to dietary intervention; smaller than statins.
Glycemic control — supportive trial evidence
Oat β-glucan's viscous gel slows gastric emptying and reduces postprandial glucose and insulin responses. Oat beta-glucan is not the subject of a specific FDA diabetes health claim, but the EU authorises the claim that beta-glucans from oats or barley eaten as part of a meal reduce the rise in blood glucose after that meal, at 4 g of beta-glucan per 30 g of available carbohydrate in the meal (Regulation (EU) No 432/2012). A meta-analysis of 103 acute feeding comparisons in 538 people found that adding oat beta-glucan to a carbohydrate meal cut the glucose response by 23 percent and the insulin response by 22 percent, with the effect confined to high molecular weight material. Over weeks rather than hours the evidence is thinner and comes from a different group of people: four trials in 350 adults with type 2 diabetes taking 2.5 to 3.5 g/day for 3 to 8 weeks found fasting glucose 0.52 mmol/L lower and HbA1c 0.21 percentage points lower, with no change in fasting insulin. Both are blood-marker results, and the longer-term set was measured in people already managing high blood sugar.
Yeast beta-glucan and colds: mixed evidence
A pooled analysis of 13 RCTs reported a lower incidence of upper respiratory tract infections with yeast beta-glucan (OR 0.345, 95% CI 0.192 to 0.620), while its own authors cautioned that heterogeneity was high and the number of studies small, but results across endpoints are mixed: the page's own Dharsono 2019 trial found yeast β-glucan reduced the severity of physical cold symptoms during an episode yet did NOT reduce cold incidence or global severity versus placebo. The two Wellmune trials that used medically confirmed infections rather than self-reported symptom logs both fell short of significance. In 97 university students the difference in symptom days was P = 0.06. In 98 adults aged 50 to 70 there were 17 confirmed infections on Wellmune and 28 on placebo, odds ratio 0.55 (95% CI 0.24 to 1.26, P = 0.15), symptom days were a trend at P = 0.067, and symptom severity did not differ. The frequently quoted positive results in marathon runners and in stressed women come from smaller trials scored on self-reported questionnaires and run by supplement-industry consultants. Mechanism: primes innate immune cells via Dectin-1. Overall a reasonable but not conclusive evidence base for seasonal respiratory-immune support.
Innate immune activation (mechanism)
Yeast β-1,3/1,6-glucans bind Dectin-1 and complement receptor 3 (CR3) on macrophages, neutrophils, and NK cells. Activates innate immune readiness without triggering inflammatory cascade — distinct from inflammatory immune-stimulants. Mechanism well-characterized; supports a role in respiratory-immune modulation. Note: this is yeast β-glucan specifically (β-1,3/1,6); oat β-glucan (β-1,3/1,4) does not have this immune profile.
Gut microbiome shifts: measured, but not a proven digestive benefit
Beta-glucan reaches the colon and is fermented there, and human trials have measured what happens, but the result is not the usual prebiotic picture. In a randomized crossover trial in mildly high-cholesterol adults, 3 g/day of high molecular weight barley beta-glucan raised Bacteroides and lowered Firmicutes, while low molecular weight material at 3 g and 5 g/day changed nothing. In a 4-week double-blind trial in adults at risk of metabolic syndrome, 6 g/day of barley beta-glucan raised faecal propionate but reduced microbial diversity and richness rather than increasing it. Neither trial reported an increase in Bifidobacterium or Lactobacillus. The one crossover trial that measured bowel function directly, giving 14 adults 3.3 g/day of extracted oat, barley or barley mutant beta-glucan for 3 weeks, found stool frequency, faecal weight and faecal pH unchanged. No trial has shown that these shifts produce a measured digestive benefit, so treat this as a mechanism rather than a result.
Mechanism of action
Viscous gel and bile acid sequestration
Oat β-glucan forms viscous gel in upper GI tract, binding bile acids and reducing their reabsorption in the ileum. Liver upregulates LDL receptor activity to make new bile acids, lowering circulating LDL. Mechanism is the basis for the FDA-authorized cholesterol claim. Processing matters: anything that breaks the polymer down to low molecular weight cuts viscosity, and in pooled feeding trials low molecular weight oat beta-glucan lost the glucose-lowering effect that high molecular weight material kept.
Slowed gastric emptying — glucose effects
Viscous β-glucan delays gastric emptying and slows carbohydrate absorption. Reduces postprandial glucose and insulin spike. This viscosity mechanism underlies the observed blood-sugar benefits. Effect is most pronounced when β-glucan is consumed with carbohydrate meals.
Dectin-1 and CR3 immune activation
Yeast β-1,3/1,6-glucans bind Dectin-1 and complement receptor 3 on macrophages, neutrophils, and NK cells. Activates innate immune readiness — primes cells for pathogen response without triggering inflammation. Distinct from oat β-1,3/1,4 which doesn't significantly bind these receptors. Proposed mechanism underlying its respiratory-immune effects.
Short-chain fatty acid production
Beta-glucans reach the colon largely intact and are fermented there to butyrate, propionate and acetate. In human trials the measured changes were a rise in faecal propionate and shifts in Bacteroides and Firmicutes; an increase in Bifidobacterium or Lactobacillus was not reported. Butyrate is the primary energy substrate for colonocytes. Prebiotic mechanism complements the direct fiber effects.
Clinical trials
This is a United States regulation, not a clinical trial. FDA authorized the claim on 23 January 1997 in response to a 1995 petition from The Quaker Oats Company. The regulation requires 3 g or more per day of beta-glucan soluble fiber and at least 0.75 g of soluble fiber per serving.
Not a study population: this card describes a United States food-labeling regulation.
This is a United States regulation, not a clinical trial. FDA authorized the claim on 23 January 1997 in response to a 1995 petition from The Quaker Oats Company. The regulation requires 3 g or more per day of beta-glucan soluble fiber and at least 0.75 g of soluble fiber per serving. Eligible sources were extended by later rulemaking and now cover oat bran, rolled oats, whole oat flour, oatrim, whole grain and dry milled barley, and barley betafiber. The regulation text is at ecfr.gov under 21 CFR 101.81.
This card summarizes a meta-analysis, not a single trial. Whitehead 2014 pooled 28 randomized trials of 3 g/day or more of oat beta-glucan and found LDL cholesterol 0.25 mmol/L lower than control (95% CI 0.20 to 0.30).
28 randomized controlled trials pooled; not a single study population.
This card summarizes a meta-analysis, not a single trial. Whitehead 2014 pooled 28 randomized trials of 3 g/day or more of oat beta-glucan and found LDL cholesterol 0.25 mmol/L lower than control (95% CI 0.20 to 0.30). Total cholesterol was 0.30 mmol/L lower. There was no evidence that dose above 3 g/day changed the result across trials using 3.0 to 12.4 g/day, nor that treatment length from 2 to 12 weeks did, and there was no effect on HDL cholesterol or triglycerides. Lowering was greater in people who started with higher LDL. This is the strongest aggregate evidence on the page.
This card describes a European regulatory opinion, not a clinical trial. In 2010 the EFSA Panel on Dietetic Products, Nutrition and Allergies assessed an Article 14 application from CreaNutrition AG and concluded that a cause and effect relationship is established between oat beta-glucan intake, at about 3 g/day, and lowering of blood LDL cholesterol.
Population not stated by the source cited on this card.
This card describes a European regulatory opinion, not a clinical trial. In 2010 the EFSA Panel on Dietetic Products, Nutrition and Allergies assessed an Article 14 application from CreaNutrition AG and concluded that a cause and effect relationship is established between oat beta-glucan intake, at about 3 g/day, and lowering of blood LDL cholesterol. The Panel found oat beta-glucan sufficiently characterised and treated lowering of LDL cholesterol as a beneficial physiological effect that decreases coronary heart disease risk. The applicant submitted 22 references, three meta-analyses and 19 randomized trials. This is a second regulator reaching the same conclusion as FDA on largely the same trial literature, not a second body of evidence.
This card summarizes a meta-analysis, not a single trial. Zhong 2021 pooled 13 randomized trials of yeast beta-glucan for upper respiratory tract infection in healthy adults.
13 randomized controlled trials pooled; not a single study population.
This card summarizes a meta-analysis, not a single trial. Zhong 2021 pooled 13 randomized trials of yeast beta-glucan for upper respiratory tract infection in healthy adults. It reported lower odds of getting an infection (OR 0.345, 95% CI 0.192 to 0.620), fewer episodes and shorter episodes. Its authors cautioned that heterogeneity was high and the number of included studies small. Individual trials disagree: Dharsono 2019 reduced symptom severity but not incidence, and Fuller 2017, which counted medically confirmed infections, missed significance on both incidence and severity. Suggestive, not definitive.
Fuller 2017: a double-blind, placebo-controlled trial of Wellmune, a yeast beta-1,3/1,6-glucan brand now owned by Kerry, at 250 mg/day for 90 days over winter, run at the University of Southampton. This evidence belongs to that specific branded material, not to yeast beta-glucan products in general.
Population not stated by the source cited on this card.
Fuller 2017: a double-blind, placebo-controlled trial of Wellmune, a yeast beta-1,3/1,6-glucan brand now owned by Kerry, at 250 mg/day for 90 days over winter, run at the University of Southampton. This evidence belongs to that specific branded material, not to yeast beta-glucan products in general. Among the 98 adults aged 50 to 70 who completed, there were 17 medically confirmed infections on Wellmune and 28 on placebo: odds ratio 0.55 (95% CI 0.24 to 1.26, P = 0.15), which is not statistically significant. Symptom days were a trend only (P = 0.067) and symptom severity did not differ. An earlier 90-day trial by the same group, in 97 university students, also missed significance on symptom days (P = 0.06). The often quoted positive results in marathon runners and in stressed women come from smaller trials scored on self-reported questionnaires rather than confirmed infections.